CompletedNot Applicable

Early External Cephalic Version (ECV) 2 Trial

Canada1,543 participantsStarted 2004-12

Plain-language summary

For women with a fetus in breech presentation, does early ECV (at 34 0/7 up to 35 weeks and 6/7 days) versus delayed ECV (not before 37 weeks and 0/7 days) increase or decrease the likelihood of cesarean section (CS)?

Who can participate

Age range14 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Women with any breech presentation
✓. A live singleton fetus
✓. Gestational age of 33 weeks 0 days to 35 weeks 6 days

Exclusion criteria

✕. Contraindications to ECV (e.g. fetal heart rate abnormalities, abruptio placenta, major life-threatening fetal anomalies, uterine anomalies, hyper-extended fetal head, rupture of membranes, severe oligohydramnios, severe polyhydramnios)
✕. Contraindications to early ECV (e.g. increased risk of preterm labour \[such as past history of preterm labour in this or previous pregnancies\], increased risk of abruptio placenta \[such as maternal hypertension\])
✕. Contraindications to labour or vaginal delivery (e.g. placenta previa, previous classical CS)
✕. Women planning delivery by CS if the fetus turns to cephalic
✕. Women planning a vaginal delivery if the fetus remains breech
✕. Women at increased risk of unstable lie (eg. grand multiparity)
✕. Previous participation in EECV2 Trial

What they're measuring

Rate of cesarean section

Timeframe: Information not available

Trial details

NCT IDNCT00141687

SponsorMcMaster University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-06

View on ClinicalTrials.gov More Breech Presentation trials